6533b85efe1ef96bd12c0747
RESEARCH PRODUCT
Pharmacokinetic evaluation of oral fenofibrate nanosuspensions and SLN in comparison to conventional suspensions of micronized drug.
Peter LangguthT. LenhardtGuy VergnaultM Tubic GrozdanisAbeer HanafyHilde Spahn-langguthPascal Greniersubject
DrugMalemedia_common.quotation_subjectPharmaceutical ScienceAdministration OralBiological AvailabilityPharmacologyModels BiologicalDosage formPharmacokineticsFenofibrateSuspensionsSolid lipid nanoparticlemedicineAnimalsComputer SimulationTissue DistributionSolubilityRats Wistarmedia_commonHypolipidemic AgentsFenofibrateChemistryLipidsBioavailabilityRatsSolubilityDrug deliveryNanoparticlesmedicine.drugdescription
An increasing number of newly developed drugs show bioavailability problems due to poor water solubility. Formulating the drugs as nanosuspensions may help to overcome these problems by increasing saturation solubility and dissolution velocity. In the present study the bioavailability of the poorly soluble fenofibrate following oral administration was investigated in rats. Four formulations were tested: a nanosuspension type DissoCube(R), one solid lipid nanoparticle (SLN) preparation and two suspensions of micronized fenofibrate as reference formulations, one suspension in sirupus simplex and a second in a solution of hydroxyethy-cellulose in physiological saline. Both colloidal drug delivery systems showed approximately two-fold bioavailability enhancements in terms of rate and extent compared to the reference formulations. No significant differences were found in AUC(0-22 h) as well as in C(max) and t(max) between the two colloidal delivery systems. In conclusion, nanosuspensions may be a suitable delivery system to improve the bioavailability of drugs with low water solubility.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2007-07-10 | Advanced drug delivery reviews |